CLEARSIDE BIOMEDICAL, INC.
CLSD US1850631045
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -14% | -61% | -4% | -26% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Thorp Clay O |
0.92 USD |
15,000 Bought |
13,800 USD |
24/02/2025 | 24/02/2025 |
| Chong Ngai Hang Victor CMO |
1.00 USD |
36,500 Bought |
36,500 USD |
01/11/2024 | 01/11/2024 |
| Chong Ngai Hang Victor CMO |
1.06 USD |
23,500 Bought |
24,910 USD |
24/06/2024 | 24/06/2024 |
| Yerxa Benjamin R O |
1.31 USD |
7,813 Bought |
10,235 USD |
15/05/2024 | 15/05/2024 |
| Gibney Anthony S O |
1.30 USD |
93,290 Bought |
121,277 USD |
17/04/2024 | 18/04/2024 |
| Gibney Anthony S O |
1.25 USD |
6,710 Bought |
8,388 USD |
17/04/2024 | 17/04/2024 |
| Chong Ngai Hang Victor CMO |
1.60 USD |
30,000 Bought |
48,000 USD |
20/03/2024 | 20/03/2024 |
| Whitmore Bradford T |
1.35 USD |
444,444 Bought |
599,999 USD |
07/02/2024 | 07/02/2024 |
| Deignan Charles A. CFO |
1.28 USD |
12,900 Sold |
16,512 USD |
18/01/2024 | 19/01/2024 |
| Lasezkay George M CEO |
1.27 USD |
18,000 Sold |
22,860 USD |
18/01/2024 | 19/01/2024 |